Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report. Issue 7 (18th June 2019)

• Record Type: Journal Article
• Authors: Trabjerg, Natacha Dencker; Rask, Christina; Jensen, Lars Henrik; Hansen, Torben Frøstrup
• Is Part Of: Clinical case reports. Volume 7:Issue 7(2019)
• Page Start: 1445
• Page End: 1449
• Publication Date: 2019-06-18
• Subjects: carcinoembryonic antigen -- colorectal cancer -- immunotherapy -- pseudoprogression -- reintroducing chemotherapy; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2262
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency. Abstract : Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency.